Neurology · 2023 · 10 citations · 31 references
Life SciencesNeurologyNeuroscienceClinical NeuroscienceNeurodegenerationNeurogeneticsAmyotrophic Lateral SclerosisMotor Neuron DiseasesNeurodegenerative Disease PharmacotherapyNeurodegenerative DiseasesNeurodegenerative DisordersNeuromuscular RehabilitationAmyotrophic Lateral Sclerosis Palliative CareAmyotrophic Lateral Sclerosis PathologyNeurodegenerative Disease EpidemiologyNeuroprotective PharmacotherapyNoninvasive Ventilation CareNutritional Support MedicationsSpeech Dysfunction
The estimated prevalence of amyotrophic lateral sclerosis (ALS) is approximately 5.2–7.9 people per 100,000 in the United States,1,2 with a worldwide ALS estimate of 4.42 per 1,000,000 population.3 Patients with ALS have progressive arm and leg weakness, speech, swallowing, and respiratory impairments, and frequent cognitive/behavioral dysfunction. Median tracheostomy-free survival from onset of weakness is 34.7 months, but progression rates vary substantially between individuals.4 Although pharmacologic treatment options remain limited, judicious use of noninvasive ventilation, adequate nutritional support, and multidisciplinary care serve as the background for a landscape that continues to evolve with increasing availability of neuroprotective treatments and targeted genetic therapies on both a clinical5 and research basis.6,7
31
ESPEN guideline clinical nutrition in neurology
R. Burgos, Emanuele Cereda, Jean Claude Desport et al. · Clinical Nutrition · 2017 · 539 citations · Full text
Agriculture, Neurology, Nutrition +11